Camp4 Therapeutics Corp financial data

Symbol
CAMP on Nasdaq
Location
One Kendall Square, Building 1400 West, 3 Rd Floor, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 468 %
Debt-to-equity -1.31K %
Return On Equity 4.85K % +12523%
Return On Assets -96.9 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20.2M shares
Common Stock, Shares, Outstanding 20.2M shares
Common Stock, Value, Issued 2K USD
Weighted Average Number of Shares Outstanding, Basic 20.2M shares +4068%
Weighted Average Number of Shares Outstanding, Diluted 20.2M shares +4068%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.5M USD
Research and Development Expense 40.2M USD +10.2%
General and Administrative Expense 16.5M USD +27.8%
Operating Income (Loss) -53.7M USD -2.89%
Nonoperating Income (Expense) 1.9M USD +413%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -51.8M USD -4.16%
Earnings Per Share, Basic 40 USD/shares +97.6%
Earnings Per Share, Diluted 40 USD/shares +97.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 39.1M USD
Other Assets, Current 333K USD
Assets, Current 41.1M USD
Property, Plant and Equipment, Net 3.41M USD
Operating Lease, Right-of-Use Asset 5.06M USD
Assets 51.3M USD
Accounts Payable, Current 1.2M USD
Employee-related Liabilities, Current 1.52M USD
Accrued Liabilities, Current 2.87M USD
Contract with Customer, Liability, Current 0 USD
Liabilities, Current 7.34M USD
Operating Lease, Liability, Noncurrent 3.89M USD
Other Liabilities, Noncurrent 2K USD
Liabilities 11.3M USD
Retained Earnings (Accumulated Deficit) -237M USD
Stockholders' Equity Attributable to Parent 40M USD
Liabilities and Equity 51.3M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.3M USD -28.2%
Net Cash Provided by (Used in) Financing Activities -151K USD +25.2%
Net Cash Provided by (Used in) Investing Activities -279K USD -1760%
Common Stock, Shares Authorized 175M shares
Common Stock, Shares, Issued 20.2M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.7M USD -29.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 40.7M USD +186%
Deferred Tax Assets, Valuation Allowance 64.9M USD +30.9%
Deferred Tax Assets, Gross 66.6M USD +28.7%
Operating Lease, Liability 7.04M USD
Payments to Acquire Property, Plant, and Equipment 279K USD +1760%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -51.8M USD -0.09%
Lessee, Operating Lease, Liability, to be Paid 7.55M USD
Property, Plant and Equipment, Gross 10.6M USD
Operating Lease, Liability, Current 3.15M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.98M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.56M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 515K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 264K USD
Deferred Tax Assets, Operating Loss Carryforwards 27.7M USD +46.1%
Preferred Stock, Shares Authorized 25M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 263K USD
Operating Lease, Payments 3.35M USD -11.5%
Additional Paid in Capital 277M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 421K USD -3.44%
Share-based Payment Arrangement, Expense 4.25M USD +27.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares